The sixth season promises an epic rebellion inside the dystopian authoritarian “hellscape”, and an ending that will leave a ...

Gilead's HIV portfolio remains dominant but faces Medicare Part D pricing pressure, limiting future growth potential. New launches like Livdelzi provide growth opportunities but are unlikely to ...

Below is Validea's guru fundamental report for GILEAD SCIENCES INC (GILD). Of the 22 guru strategies we follow, GILD rates highest using our Multi-Factor Investor model based on the published ...

Below is Validea's guru fundamental report for GILEAD SCIENCES INC (GILD). Of the 22 guru strategies we follow, GILD rates highest using our Twin Momentum Investor model based on the published ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines for virology, oncology and other therapeutic areas in the United States, Europe, and ...

Gilead Sciences has declared a quarterly dividend to stockholders on record at the close of business on March 14, 2025. (Reuters) Gilead Sciences, with a market capitalization of $143.8 billion ...

In the latest in a series of training exercises, U.S. soldiers are confronting the realities of defending one of NATO’s most ...

Anna Commander is a Newsweek Editor and writer based in Florida. Her focus is reporting on crime, weather and breaking news. She has covered weather, and major breaking news events in South Florida.

In a phase 2 trial, an antiretroviral combination developed by Gilead Sciences and MSD suppressed HIV with a single weekly oral dose, raising the hope of a new treatment option for patients.